Training workshop on screening, diagnosis and treatment of hepatitis B and C
Session 1A

Viral hepatitis:
global overview and progress update
Viral hepatitis – global overview
January 2020
Hepatitis B global overview, 2015

Incidence:
Chronic HBV infection in children under 5 reduced from 4.7% to 1.3% (immunization)

Prevalence:
257 million people living with HBV 68% in Africa /Western Pacific

This slide shows the epidemiological situation of hepatitis B. The map on the right-hand side shows the cumulative incidence of chronic HBV infection in children under five as represented by the prevalence of hepatitis B surface antigen. This cumulative incidence of chronic HBV infection in children under 5 years fell from 4.7% in the pre-vaccine era to 1.3% in 2015. This considerable reduction of incidence is attributable to progress in immunization coverage.

On the graph at the bottom of the slide, you can see the number of people living with HBV in the various WHO regions. There are 257 million persons living with HBV in the world 68% of these are living in the African or in the Western Pacific regions.
This slide shows the epidemiological situation of HCV infection. The map at the top shows the incidence of HCV infection by WHO region. Overall, there are still 1.75 million new infections in the world each year. This is more than the number of persons who were cured in 2015 – indicating a growing epidemic. Unsafe health-care injections and injection drug use still cause transmission of HCV in many hotspots, particularly in the Eastern Mediterranean and European regions. At the bottom of this slide, you can see the total number of persons living with HCV infection by region; 71 million of persons are living with HCV. The number of persons with HCV infection is about the same in all regions, but there are differences across countries and sometimes within countries.
Hepatitis / HIV coinfection, 2015

In 2015, the Global Fund board agreed to cover the cost of management of coinfections.

- 257 million HBV infections
- 71 million HCV infections
- 37 million HIV infections
- 2.7 million HIV+ and HBsAg+
- 2.3 million HIV+ and anti-HCV+

HIV- Hepatitis B coinfections are estimated at 2.7 million
HIV- Hepatitis C coinfections are estimated at 2.3 million
If we look at mortality, we see that over the last 10 years, for HIV, tuberculosis and malaria, the numbers have decreased. For hepatitis, the orange line, you will note that mortality is increasing, with 1.34 million deaths in 2015. 96% of the mortality from viral hepatitis is attributable to the sequelae of HBV and HCV infections, which include cirrhosis and hepatocellular carcinoma.

How were we doing in 2015 to reverse that trend? Let’s review together the status of the various core interventions of the global strategy.
The majority of death is attributable to chronic infection with hepatitis B or C
Global Strategy on Viral Hepatitis Elimination (2016–2021)

In 2016, during the World Health Assembly, Member States endorsed the Global Strategy on Hepatitis that called for elimination of hepatitis as a public health threat by 2030

SDG 3.3
Goal = Eliminate viral hepatitis as a major public health threat by 2030
The World Health Assembly pledged to reach elimination

Five core interventions with sufficient coverage would lead to elimination (incidence – 90%, mortality – 65%)

<table>
<thead>
<tr>
<th>Interventions</th>
<th>Indicator</th>
<th>2015</th>
<th>2020</th>
<th>2030</th>
</tr>
</thead>
<tbody>
<tr>
<td>3 doses of HBV vaccine</td>
<td>Coverage</td>
<td>84%</td>
<td>90%</td>
<td>90%</td>
</tr>
<tr>
<td>HBV PMTCT</td>
<td>Coverage</td>
<td>39%</td>
<td>50%</td>
<td>90%</td>
</tr>
<tr>
<td>Blood / injection safety</td>
<td>Screened donations</td>
<td>97%</td>
<td>100%</td>
<td>100%</td>
</tr>
<tr>
<td></td>
<td>Safe injections</td>
<td>95%</td>
<td>100%</td>
<td>100%</td>
</tr>
<tr>
<td>Harm reduction</td>
<td>Sets/PWID/year</td>
<td>27</td>
<td>200</td>
<td>300</td>
</tr>
<tr>
<td>HBV and HCV testing and treatment</td>
<td>% diagnosed</td>
<td>9/20%</td>
<td>30%</td>
<td>90%</td>
</tr>
<tr>
<td></td>
<td>% treated</td>
<td>8/7%</td>
<td>N/A</td>
<td>80%</td>
</tr>
</tbody>
</table>
As a baseline at 2015, there is major gaps in the global response to hepatitis action in HBV birth dose, harm reduction, testing and treatment. We have a long way to go towards elimination of viral hepatitis as a public health threat by 2030.
WHO delivered most of the global goods needed

2015
- Elimination strategy
- HBV Guidelines

2016
- Revised HCV Guidelines
- National plan manual

2017
- Baseline estimates: Global Hepatitis Report
- HBV/HCV testing Guidelines
- Injection safety campaign

2018
- Global hepatitis reporting system
- HCV treatment Guidelines: Treat All
- Cost effectiveness calculators (HBV/HCV)

2019
- Consolidated strategic information guidelines (Feb 2019)
- HBV PMTCT recommendations on antiviral medicine use in pregnancy (early 2020)

WHO has delivered most of the global goods needed to guide national action on viral hepatitis elimination
More and more countries are working on comprehensive national action plans for viral hepatitis. WHO has established the new global reporting system for hepatitis, and more countries are reporting into this system.
Prevention interventions: Low coverage of harm reduction globally and of timely birth dose in Africa

- Coverage of interventions as proportion of 2030 target at baseline

- Harm reduction (2017): No progress to date
- HBV timely birth dose (2017): Incomplete, major actions
- 3rd dose HBV vaccine (2017): On track, gaps
- Injection safety (2010-2015): On track, gaps

Source: WHO / UNICEF, Demographic and Health Surveys, and Lancet publication
First in terms of hepatitis B vaccine we have seen major progress since 2000, with 84% global coverage for the third dose in 2015. High vaccine coverage successfully reduces incidence in children. However, to reduce the incidence of these infections acquired at birth, which are most at risk for progression towards chronic liver diseases, another intervention is needed.
That other intervention is the birth dose. On the slide, you can see the coverage of the birth dose of hepatitis B vaccine between 2000 and 2015 for selected regions. We have had success stories in the Western Pacific region where perinatal transmission was a major problem. In the Americas, coverage tremendously increased also. However, global coverage (as a dashed black line) is still low at 39% and in the African region which is highly endemic for hepatitis B, the coverage of the timely birth dose is only 10%.
Injection safety: frequency and safety

- New data from Demographic and Health Surveys:
  3.9% unsafe health-care injections worldwide in 2010–2017

This graph shows health care injections per year and the red graph shows unsafe injections.
Unsafe injections is an important element. The goal is to have 100% safe injections (or, conversely 0% unsafe injections)
For comprehensive harm reduction services in the context of policies that prevent stigma and discrimination, we are far from the target. By 2030, we should be at 300 needle and syringe sets per person and per year. However, of the 11.8 million persons who inject drugs worldwide, on the left hand side, too few have access to satisfactory harm reduction services. Our estimated number of needle/syringe distributed per person who inject drugs per year is low at 33 while we should reach at least 200 by 2020 (On the right hand side).
Let us look at testing and Treatment, what we call the cascade of care, first for HBV: many of the 257 million people living with chronic hbv remain undiagnosed, and even fewer, about 4.5 million were on treatment in 2016.
Cascade of cure for HCV infection by WHO region, 2017

- Most treatment given in about 10 champion countries

No progress to date | Incomplete, minor actions taken | Incomplete, but major actions | On track, gaps | On track, minor gaps

- 2014: <200 000
- 2015: 1.1 million
- 2016: 1.7 million
- 2017: 2.1 million
- Total: ~5 million treated with DAAs (by 31 Dec. 2017)

For HCV, we also have a major testing gap, in all parts of the world (shown in the different colours).
At best, 20% are being diagnosed, and about 3 million people had received DAAs, cumulatively by 2017.
The price of antiviral medicines is decreasing rapidly

Annual treatment with tenofovir for HBV decreased from US$ 208 to US$ 28 between 2004 and 2017

The price of a course of sofosbuvir for an HCV cure decreased from US$ 84 000 to US$ <200 between 2014 and 2017

HBV

<table>
<thead>
<tr>
<th>Year</th>
<th>Annual treatment cost (US$)</th>
</tr>
</thead>
<tbody>
<tr>
<td>2004</td>
<td>US$ 208</td>
</tr>
<tr>
<td>2005</td>
<td>US$ 166</td>
</tr>
<tr>
<td>2006</td>
<td>US$ 131</td>
</tr>
<tr>
<td>2007</td>
<td>US$ 100</td>
</tr>
<tr>
<td>2008</td>
<td>US$ 81</td>
</tr>
<tr>
<td>2009</td>
<td>US$ 65</td>
</tr>
<tr>
<td>2010</td>
<td>US$ 52</td>
</tr>
<tr>
<td>2011</td>
<td>US$ 40</td>
</tr>
<tr>
<td>2012</td>
<td>US$ 32</td>
</tr>
<tr>
<td>2013</td>
<td>US$ 28</td>
</tr>
<tr>
<td>2014</td>
<td>US$ 28</td>
</tr>
<tr>
<td>2015</td>
<td>US$ 28</td>
</tr>
<tr>
<td>2016</td>
<td>US$ 28</td>
</tr>
<tr>
<td>2017</td>
<td>US$ 28</td>
</tr>
</tbody>
</table>

HCV

<table>
<thead>
<tr>
<th>Year</th>
<th>Price per course (US$) log scale</th>
</tr>
</thead>
<tbody>
<tr>
<td>2014</td>
<td>US$ 84 000</td>
</tr>
<tr>
<td>2015</td>
<td>US$ 70 000</td>
</tr>
<tr>
<td>2016</td>
<td>US$ 50 000</td>
</tr>
<tr>
<td>2017</td>
<td>US$ &lt;200</td>
</tr>
</tbody>
</table>

At present, we have a favourable environment to control viral hepatitis because the cost of highly effective drugs has been markedly reduced in the past decade, which has made hepatitis B and C treatment affordable for countries. Several countries are starting their national viral hepatitis control programmes.

When treatment become highly effective and cheaper, it is more cost effective to treat a health condition en masse under the umbrella of a public health programme.

Tenofovir is the main drug used for the treatment of hepatitis B and its cost has reduced by more than 10-fold in the past 15 years. Similarly, sofosbuvir is the backbone of hepatitis C treatment and its cost has reduced by more than 500-fold since it was first approved for use in 2014.
Missed opportunities to optimize procurement of generic direct-acting antivirals (DAAs) to cure HCV infection

62% of people with HCV live in countries that have access to generic DAAs for as low as US$ 90 (in green)

In reality, the price of a 3-month course of generic DAAs varies greatly by location

No progress to date  Incomplete, minor actions taken  Incomplete, but major actions  On track, gaps  On track, minor gaps
Global status: summary

- Progress in immunization, injection safety and blood safety

- Setbacks in timely birth dose in Africa and on harm reduction

- Scaled up programmes in country with very high HCV burden

- Limited testing and treatment scaling up in other countries
Way forward

• Strengthen country support tailored to their unique contexts

• Simplify to integrate with HIV, TB, Malaria, communicable and non-communicable diseases

• Strengthen partnerships
  – Within WHO headquarters
  – With country and regions
  – With external partners

• Advocate for implementation within the Universal Health Coverage (UHC) framework